Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biochips in Drug Development

26.06.2003


Figure 1: Ligand fishing (BIA-MS coupling)


Figure 2: ADME assays of small compounds binding to HSA


Biomolecular interaction analysis (BIA) using SPR (surface plasmon resonance) biosensors is now utilised increasingly in nearly all phases of drug development. The BIA system consists out of a light source emitting near infrared light, a sensor microchip, an automated liquid handling system with constant flow and a diode array position-sensitive detector. One of the two interacting partners (referred to as the ligand) is immobilized on the sensor surface. The other binding partner, called the analyte, is directed over the surface in a constant flow system allowing to monitor the interaction of the binding partners in “real time”.

BIA covers a broad range of applications in target identification and validation, secondary screens and lead optimisation, early ADME assays as well as testing immunoreactivity.

Assay development and functional assays of proteins are the most commonly used areas of applications of BIA in drug development.



Advantages of SPR-based measurements are the possibility to measure in real time without the need of labelling yielding highly reproducible kinetic data with low sample consumption.

Ligand fishing

BIA-technology is ideally suited as a micro-affinity purification platform allowing on-line detection of binding events and the direct quantification of bound material on biological surfaces of interest.

Kinetic parameters may be obtained as additional information. Provided that a binding partner has been captured on the sensor chip it can be recovered by a gentle elution for further downstream analyses like mass spectrometry or western blot analysis (see figure 1).

In comparison to classical chromatographic methods biosensor systems show reduced unspecific binding, are compatible with small volume recovery and are readily automated.

The identification of unknown ligands is of particular interest for revealing function of orphan receptors, for the detection of cellular interaction networks and for testing the biocompatibility of novel surface coatings.

Target validation

Genomics and proteomics based techniques have provided a lot of new potential targets which has to be validated to prove that a DNA, RNA or protein molecule is directly involved in a disease process and is therefore a suitable target for the development of new therapeutic compounds.

The assessment of biological function, involvement in biological pathways and role in pathogenesis of potential targets can be achieved by mapping and validation of protein interaction networks in vivo and in vitro.

Yeast two hybrid and phage display are classical approaches for systematic protein interaction screening capable to probe millions of interactions. Positives obtained from these screening technologies can be validated using BIA technology.

Furthermore, additional parameters relevant for the interaction of interest can be investigated. This could be interactions with multiple components, effects of cofactors, pH-changes or the role of posttranslational modifications.

Lead optimisation

Hit validation is needed to determine whether a molecule identified in a screen or assay will eventually lead to a drug.

Therefore secondary assays generating data about potency, selectivity and functional biochemical activity have to be performed.

BIA technology has an enormous capability for the rapid confirmation of hits from high throughput screens by a comprehensive kinetic characterisation of potential lead compounds.

Information about affinities, rates of association and dissociation in complex formation and binding stoichiometries is very valuable for a ranking and optimisation of lead compounds. Even compounds binding with low affinity or transient kinetics, often found in early phases of drug development, can accurately be identified.

The kinetic information obtained by functional assays together with the knowledge about structural properties of biomolecules allows predictions on structure activity relationships.

Lead optimisation is an iterative process involving computer-assisted molecular modelling, chemical synthesis of new compounds and functional assays.

BIA technology is used in lead optimisation by linking compound structural information with a comprehensive kinetic characterisation of ligand binding.

ADME

ADME assays (adsorption, distribution, metabolism, elimination) become more and more important even in the earlier phases of the drug development process.

BIA assays provide very valuable information for a cost-effective in vitro characterisation of potential drug candidates in early ADME studies, although there are no methods available for accurately predicting what will happen to a drug in vivo.

SPR biosensor technology has already been applied for the binding of potential drug candidates to serum proteins, for analysing the adsorption of small molecules to artificial membranes immobilised on sensor chips and for measuring the influence of compounds on metabolic pathways.

The pharmacokinetic properties of small molecule drugs are a function of the reversible binding to serum proteins such as serum albumin, alpha 1-acid glycoprotein or gamma globulins, reducing the bioavailibility of the drug (see figure 2).

Biaffin offers a BIA assay for analysing the binding of small molecule compounds to high density serum protein surfaces yielding valuable information about affinitiy, solubility and binding stoichiometry of potential drug candidates.

Immune response

Newly designed pharmaceuticals can cause an unwanted immune response. In preclinical studies such potentials can be recognised in animal studies.

BIA technology can detect antibodies against new drugs in animal serum samples. With appropriate control experiments positive binding signals of low antibody levels can clearly be identified as a specific signal despite of the complexity of the protein mixture in serum samples.

Dr. Stephan Drewianka | Biaffin GmbH & Co KG
Further information:
http://www.biaffin.com/drug_development.htm
http://www.innovations-report.de/html/profile/profil-1117.html

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>